Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment

References

1. 1.↵
   2. Waarts MR,
   3. Stonestrom AJ,
   4. Park YC,
   5. Levine RL.

   Targeting mutations in cancer. J Clin Invest. 2022; 132: e154943.
2. 2.↵
   2. Yu HA,
   3. Arcila ME,
   4. Rekhtman N,
   5. Sima CS,
   6. Zakowski MF,
   7. Pao W, et al.

   Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240–7.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Johnson DB,
   3. Menzies AM,
   4. Zimmer L,
   5. Eroglu Z,
   6. Ye F,
   7. Zhao S, et al.

   Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015; 51: 2792–9.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Hugo W,
   3. Shi H,
   4. Sun L,
   5. Piva M,
   6. Song C,
   7. Kong X, et al.

   Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015; 162: 1271–85.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Gaggianesi M,
   3. Di Franco S,
   4. Pantina VD,
   5. Porcelli G,
   6. D’Accardo C,
   7. Verona F, et al.

   Messing up the cancer stem cell chemoresistance mechanisms supported by tumor microenvironment. Front Oncol. 2021; 11: 702642.
6. 6.↵
   2. Wang T,
   3. Xiao M,
   4. Ge Y,
   5. Krepler C,
   6. Belser E,
   7. Lopez-Coral A, et al.

   BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Clin Cancer Res. 2015; 21: 1652–64.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Hipp MM,
   3. Hilf N,
   4. Walter S,
   5. Werth D,
   6. Brauer KM,
   7. Radsak MP, et al.

   Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008; 111: 5610–20.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Propper DJ,
   3. Balkwill FR.

   Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19: 237–53.

   OpenUrlPubMed
9. 9.↵
   2. Gong K,
   3. Guo G,
   4. Gerber DE,
   5. Gao B,
   6. Peyton M,
   7. Huang C, et al.

   TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018; 128: 2500–18.

   OpenUrlCrossRefPubMed
10. 10.
    2. Gong K,
    3. Guo G,
    4. Panchani N,
    5. Bender ME,
    6. Gerber DE,
    7. Minna JD, et al.

    EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat Cancer. 2020; 1: 394–409.

    OpenUrlPubMed
11. 11.↵
    2. Gong K,
    3. Guo G,
    4. Beckley NA,
    5. Yang X,
    6. Zhang Y,
    7. Gerber DE, et al.

    Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nat Commun. 2021; 12: 7014.

    OpenUrlPubMed
12. 12.↵
    2. Guo G,
    3. Gong K,
    4. Puliyappadamba VT,
    5. Panchani N,
    6. Pan E,
    7. Mukherjee B, et al.

    Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro Oncol. 2019; 21: 1529–39.

    OpenUrlPubMed
13. 13.↵
    2. Lu H,
    3. Zhang S,
    4. Wu J,
    5. Chen M,
    6. Cai MC,
    7. Fu Y, et al.

    Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Can Res. 2018; 24: 6066–77.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Zimmer L,
    3. Livingstone E,
    4. Krackhardt A,
    5. Schultz ES,
    6. Göppner D,
    7. Assaf C, et al.

    Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF^V600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. Eur J Cancer. 2021; 158: 72–84.

    OpenUrlPubMed
15. 15.
    2. Gogas H,
    3. Dréno B,
    4. Larkin J,
    5. Demidov L,
    6. Stroyakovskiy D,
    7. Eroglu Z, et al.

    Cobimetinib plus atezolizumab in BRAF^V600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol. 2021; 32: 384–94.

    OpenUrlPubMed
16. 16.
    2. Ribas A,
    3. Algazi A,
    4. Ascierto PA,
    5. Butler MO,
    6. Chandra S,
    7. Gordon M, et al.

    PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020; 11: 6262.

    OpenUrlPubMed
17. 17.
    2. Hodi FS,
    3. Lawrence D,
    4. Lezcano C,
    5. Wu X,
    6. Zhou J,
    7. Sasada T, et al.

    Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014; 2: 632–42.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    2. Ribas A,
    3. Lawrence D,
    4. Atkinson V,
    5. Agarwal S,
    6. Miller WH Jr.,
    7. Carlino MS, et al.

    Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019; 25: 936–40.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Hong DS,
    3. Fakih MG,
    4. Strickler JH,
    5. Desai J,
    6. Durm GA,
    7. Shapiro GI, et al.

    KRAS^G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020; 383: 1207–17.

    OpenUrlCrossRefPubMed